Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1794-1801

  Deng, Yujie ^a   Wang, Hui ^a   Lu, Yan ^a   Liu, Shuang ^a   Zhang, Qiang ^a   Huang, Jian ^a   Zhu, Rongfeng ^a   Yang, Jian ^a   Zhang, Rong ^a   Zhang, Di ^a   Shen, Weili ^b   Ning, Guang ^a   Yang, Ying ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; CHEMERIN; FARNESOID X RECEPTOR; LUCIFERASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; WILD TYPE;

ANIMALS; CELLS, CULTURED; CHEMOKINES; DISEASE PROGRESSION; DOWN-REGULATION; FATTY LIVER; GENE EXPRESSION REGULATION; HEK293 CELLS; HEP G2 CELLS; HUMANS; ISOXAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84876749355     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2126     Document Type: Article

References (37)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346:1221-1231.
2. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820-1832.
3. Anstee QM, Goldin RD. Mouse models in non-Alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16.
4. Kirsch R, Clarkson V, Shephard EG, et al. Rodent nutritional model of non-Alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol. 2003;18:1272-1282.
5. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957-969.
6. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498-3504.
7. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403-409.
8. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol. 2005;174:244-251.
9. Zabel BA, Nakae S, Zuniga L, et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008;205:2207-2220.
10. Barnea G, Strapps W, Herrada G, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci USA. 2008;105:64-69.
11. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005;175:487-493.
12. Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem. 2005;280:34661-34666.
13. Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med. 2008;205:2187-2190.
14. Goralski, KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175-28188.
15. Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-Alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45:235-242.
16. Bozaoglu, K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94:3085-3088.
17. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-α. Endocrinology. 2010;151: 2590-2602.
18. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010;72:342-348.
19. Watanabe M., Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484-489.
20. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA. 2006;103:1006-1011.
21. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010; 51:771-784.
22. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-Activated receptor-gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003;17:259-272.
23. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17: 988-997.
24. Xing X, Burgermeister E, Geisler F, et al.. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology. 2009; 49:979-988.
25. Lee FY, Kast-Woelbern HR, Chang J, et al. -Crystallin is a target gene of the farnesoid X-Activated receptor in human livers. J Biol Chem. 2005;280:31792-31800.
26. Ge X, Yin L, Ma H, Li T, Chiang JY, Zhang Y. Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis. J Lipid Res. 2011;52:1561-1568.
27. MaX,XuL,WangS, et al. Deletion of steroid receptor coactivator-3 gene ameliorates hepatic steatosis. J Hepatol. 2011;55:445-452.
28. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023-1034.
29. Zhao L, Yamaguchi Y, Sharif S, et al. Chemerin 158K is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J Biol Chem. 2011;286:39520-39527
30. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977-985.
31. Bozaoglu, K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-4694.
32. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009;58:2731-2740.
33. Kukla M, Zwirska-Korczala K, Gabriel A, et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat. 2010; 17:661-667.
34. Ren RZ, Zhang X, Xu J, et al. Chronic ethanol consumption increases the levels of chemerin in the serum and adipose tissue of humans and rats. Acta Pharmacol Sin. 2012;33:652-659.
35. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev. 2008;60:311-357.
36. Du XY, Leung LL. Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochim Biophys Sin (Shanghai). 2009;41:973-979.
37. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48: 670-678.